# Safety and Tolerability of SHR-1918 in Healthy Subjects

> **NCT05432544** · PHASE1 · UNKNOWN · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 72 (actual)

## Conditions studied

- Hyperlipemia

## Interventions

- **DRUG:** SHR-1918
- **DRUG:** SHR-1918 placebo

## Key facts

- **NCT ID:** NCT05432544
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-27
- **Primary completion:** 2023-12-11
- **Final completion:** 2023-12-12
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432544, "Safety and Tolerability of SHR-1918 in Healthy Subjects". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05432544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*